RS PHARMA
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
28-06
micro format · 33 days before the deadline
2025
31-12
Financial
Highest result from 2023 to 2025net €76,398 ▲10.5%
The operating result of €103,070 and the net result of €76,398 are both a record.
06-08
micro format · 6 days late
2024
31-12
Financial
Liquidity more than doubledcurrent ratio 7.02
The current ratio rises from 2.92 to 7.02. Short-term debt falls from €21,602 to €17,833.
31-12
Financial
Equity above €100,000equity €111,842 ▲162%
With a profit in every financial year since 2023, equity grows to €111,842.
28-08
micro format · 28 days late
2023
20-04
Gazette deed
IncorporationStarting capital €5,000 · Appointment: HACHOUM Hind (director) · Founder9 points ▸
Gazette deed
Incorporation
Starting capital €5,000 · Appointment: HACHOUM Hind (director) · Founder9 points ▸
- Incorporation, 13-04-2023
- Founder, HACHOUM Hind
- Founding capital, €5,000
- Capital
- Other provision, 06-05-2024
- Registered office clause, “1082 Berchem-Sainte-Agathe,Rue de Grand-Bigard,107” (deed in French)
- Director appointment, HACHOUM Hind (director (not named in the articles))
- Pre-incorporation commitments, “takeover, tous engagements,obligations et activités entreprises par la fondatrice au nom et pour compte de la société en formation” (deed in French)
- Power of attorney, Charles HUYLEBROUCK
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank